HER2/EGFR in Cancer Research
Open access
Peer reviewed
Scollr summary
What this paper is about
Preliminary synthesis indicates that HER2-low tumors exhibit distinct survival trajectories compared to HER2-positive cohorts, often influenced by Hormone Receptor (HR) co-expression and the type of targeted therapy received.
Full abstract
Read the full abstract
Background The emergence of HER2-low breast cancer as a distinct clinical entity has challenged the traditional binary classification of HER2 status. This systematic review aims to evaluate the disparities in Progression-Free Survival (PFS) and Overall Survival (OS) between HER2-low and HER2-positive breast cancer patients. Methods A systematic search was performed across PubMed, Scopus, Cochrane Library, ESMO and ASCO for studies published through January 2026. The Clinical trials and observational studies reporting Progression-Free Survival (PFS) and Overall Survival (OS) with Hazard Ratios (HR) were included. Due to significant clinical and methodological heterogeneity, a formal meta-analysis was deemed inappropriate; consequently, evidence was synthesized qualitatively following the Synthesis Without Meta-analysis (SWiM) guidelines. The protocol was prospectively registered in PROSPERO (CRD420261293004). Results A total of 536 records were identified; after removing 356 duplicates, 180 were screened, and 10 trials met the inclusion criteria. Preliminary synthesis indicates that HER2-low tumors exhibit distinct survival trajectories compared to HER2-positive cohorts, often influenced by Hormone Receptor (HR) co-expression and the type of targeted therapy received. Conclusion Understanding survival disparities is crucial for optimizing treatment sequencing in the era of antibody-drug conjugates (ADCs). Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420261293004.
Direct answer
What can I do from this paper page?
Use this page to scan "Survival disparities in HER2-low versus HER2-positive breast cancer: a systematic review of progression-free survival and overall survival" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow HER2/EGFR in Cancer Research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Soewoto2026Survival,
title = {Survival disparities in HER2-low versus HER2-positive breast cancer: a systematic review of progression-free survival and overall survival},
author = {Widyanti Soewoto and Ida Bagus Budhi S. A. and Wibisono and Kristanto Yuli Yarso and Joko Wibowo Sentoso},
journal = {Frontiers in Oncology},
year = {2026},
doi = {10.3389/fonc.2026.1839945},
url = {https://doi.org/10.3389/fonc.2026.1839945}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new HER2/EGFR in Cancer Research papers?
Follow HER2/EGFR in Cancer Research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Survival disparities in HER2-low versus HER2-positive breast cancer: a systematic review of progression-free survival and overall survival. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app